AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates

Loading news article.

AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates | WAPE

AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates

Article summary

Related companies

Comments —